

## Tips in Managing Anxiety Disorders in Primary Care


Niraj Ahuja  
Consultant Psychiatrist

## Anxiety

- Normal anxiety is adaptive
- An internal response to perceived threat  
*or*  
to absence of people/objects that signify safety  
*and*  
can result in cognitive and somatic symptoms

Niraj Ahuja, 18th March 2015


## Anxiety



Beck et al (1985) Anxiety Disorders and Phobias: A Cognitive Perspective

Niraj Ahuja, 18th March 2015

## Yerkes Dodson Curve (1908)



Yerkes RM, Dodson JD (1908). J Compar Neurol Psycho 18: 459-482

Niraj Ahuja, 18th March 2015

People can often try to alleviate the unpleasant feeling of anxiety by:

1. Avoiding the trigger
2. Developing a “safety behaviour” (e.g. having someone else accompany them)
3. Using a substance or “as needed” medication


## Anxiety as a Disorder





- Severity of symptoms
- Significant subjective distress or disability
- **NICE 2011:** Do not rely solely on the number, severity and duration of symptoms, but **also considers the degree of distress and functional impairment**


## Anxiety Disorders

- NICE 2011 CMHD
  - Consider GAD in those with anxiety/significant worry, and in frequent attendees in primary care who:
    - have a chronic physical health problem, or
    - are seeking reassurance about somatic symptoms, or
    - are repeatedly worrying about a wide range of different issues
- Differentiate between types of anxiety disorders and note any co-morbidities

## Anxiety Disorders







Northumberland, Tyne and Wear NHS Foundation Trust

## Common Mental Health Disorders

- Affect ~15% of population at any time
- GAD 4.4%
- OCD 1.1%
- Panic disorder 1.1%
- Phobias 1.4%
- Mod-severe depression 2.3%
- PTSD 3%

\*One week prevalence from the Office of National Statistics 2007 National Survey  
Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust

Focus of the intervention	Nature of the intervention
<p><b>Step 3:</b> Persistent subthreshold depressive symptoms or mild to moderate depression that has not responded to a low-intensity intervention, initial presentation of moderate or severe depression, GAD with marked functional impairment or that has not responded to a low-intensity intervention, moderate to severe panic disorder, OCD with moderate or severe functional impairment, PTSD.</p>	<p><b>Depression:</b> CBT, IPT, behavioural activation, behavioural couples therapy, counselling<sup>2</sup>, short-term psychodynamic psychotherapy<sup>3</sup>, antidepressants, combined interventions, collaborative care<sup>4</sup>, self-help groups.</p> <p><b>GAD:</b> CBT, applied relaxation, drug treatment, combined interventions, self-help groups.</p> <p><b>Panic disorder:</b> CBT, antidepressants, self-help groups.</p> <p><b>OCD:</b> CBT (including ERP), antidepressants, combined interventions and case management, self-help groups.</p> <p><b>PTSD:</b> Trauma-focused CBT, EMDR, drug treatment.</p> <p><b>All disorders:</b> Support groups, befriending, rehabilitation programmes, educational and employment support services; referral for further assessment and interventions.</p>
<p><b>Step 2:</b> Persistent subthreshold depressive symptoms or mild to moderate depression; GAD, mild to moderate panic disorder; mild to moderate OCD; PTSD (including people with mild to moderate PTSD).</p>	<p><b>Depression:</b> Individual facilitated self-help, computerised CBT, structured physical activity, group-based peer support (self-help) programmes<sup>5</sup>, non-directive counselling delivered at home<sup>6</sup>, antidepressants, self-help groups.</p> <p><b>GAD and panic disorder:</b> Individual non-facilitated and facilitated self-help, psychoeducational groups, self-help groups.</p> <p><b>OCD:</b> Individual or group CBT (including ERP), self-help groups.</p> <p><b>PTSD:</b> Trauma-focused CBT or EMDR.</p> <p><b>All disorders:</b> Support groups, educational and employment support services; referral for further assessment and interventions.</p>
<p><b>Step 1:</b> All known and suspected presentations of common mental health disorders.</p>	<p><b>All disorders:</b> Identification, assessment, psychoeducation, active monitoring; referral for further assessment and interventions.</p>

When a person presents with a common MH disorder **AND** harmful drinking or alcohol dependence, refer them for treatment of the alcohol misuse **FIRST**

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust

## BAP Guidelines

**Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology**

Journal of Psychopharmacology 1-31  
© The Author(s) 2014  
Reprints and permissions: [sagepub.co.uk/journalsPermissions.nav](http://sagepub.co.uk/journalsPermissions.nav)  
DOI: 10.1177/0269881114525674  
[jcp.sagepub.com](http://jcp.sagepub.com)  
SAGE

David S Baldwin<sup>1,2</sup>, Ian M Anderson<sup>3</sup>, David J Nutt<sup>4</sup>, Christer Allgulander<sup>5</sup>, Borwin Bandelow<sup>6</sup>, Johan A den Boer<sup>7,8</sup>, David M Christmas<sup>9</sup>, Simon Davies<sup>10</sup>, Naomi Fineberg<sup>11</sup>, Nicky Lidbetter<sup>12</sup>, Andrea Malizia<sup>13</sup>, Paul McCrone<sup>14</sup>, Daniel Nabarro<sup>15</sup>, Catherine O'Neill<sup>12</sup>, Jan Scott<sup>16</sup>, Nic van der Wee<sup>17</sup> and Hans-Ulrich Wittchen<sup>18</sup>

Baldwin et al (2014) BAP Guidelines  
Niraj Ahuja, 18th March 2015

## Generalised Anxiety Disorder

Northumberland, Tyne and Wear  
NHS Foundation Trust

- Detection:
  - In GAD, look for co-morbid depression and excess alcohol consumptions
  - In patients with medically unexplained physical symptoms and depression, look for anxiety
- Psychological treatment: CBT, Applied Relaxation
- *Do NOT initially combine CBT and drug treatment*
- Drug treatment
  - SSRIs
  - SNRIs
  - Pregabalin
  - Buspirone, Trazodone, Agomelatine, Benzodiazepines (AZM, DZM, LZM), Imipramine, Quetiapine, Hydroxyzine

Baldwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear  
NHS Foundation Trust

## GAD-7

Over the last 2 weeks, how often have you been bothered by the following problems?  
(Use "✓" to indicate your answer)

	Not at all	Several days	More than half the days	Nearly every day
1. Feeling nervous, anxious or on edge	0	1	2	3
2. Not being able to stop or control worrying	0	1	2	3
3. Worrying too much about different things	0	1	2	3
4. Trouble relaxing	0	1	2	3
5. Being so restless that it is hard to sit still	0	1	2	3
6. Becoming easily annoyed or irritable	0	1	2	3
7. Feeling afraid as if something awful might happen	0	1	2	3


(For office coding: Total Score T = \_\_\_\_ + \_\_\_\_ + \_\_\_\_)

Cut off Scores = 5 (mild), 10 (moderate), and 15 (severe)

Sensitivity = 89%; Specificity = 82% for GAD (score 10)

Niraj Ahuja, 18th March 2015

## CBT

Northumberland, Tyne and Wear  
NHS Foundation Trust


Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear  
NHS Foundation Trust


## CBT Resources

- Overcoming Anxiety - by Chris Williams
- Mind over Mood - by Dennis Greenberger and Christine Padesky
- Living Life to the Full  
[www.lltff.com](http://www.lltff.com)


Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear 					
NHS Foundation Trust					
Licensed antidepressant indications in anxiety disorders					
	GAD	Panic	OCD	PTSD	SAD
Fluoxetine			YES		
Citalopram		YES			
Escitalopram	YES	YES	YES		YES
Sertraline			YES	YES	
Paroxetine	YES	YES	YES	YES	YES
Fluvoxamine			YES		
Venlafaxine	YES				YES (XL)
Duloxetine					
Clomipramine			YES		YES
Trazodone	YES				
Moclobemide					YES

Niraj Ahuja, 18th March 2015


Northumberland, Tyne and Wear 		
NHS Foundation Trust		
Generalised Anxiety Disorder	Licensed (BNF)	BAP Guidance
Fluoxetine		
Citalopram		YES
Escitalopram	YES	YES
Sertraline		YES
Paroxetine	YES	YES
Venlafaxine	YES (MR)	YES
Duloxetine	YES	YES
Trazodone	YES	YES
Buspirone		YES
Agomelatine		YES
Imipramine		YES
Benzodiazepines	AZM, DZM, LZM, CDP, OZM	AZM, DZM, LZM
Quetiapine		YES
Hydroxyzine		YES

15

Northumberland, Tyne and Wear 	
NHS Foundation Trust	
Antidepressants – start slow	
Anxiety Disorders	<ul style="list-style-type: none"> <li>Patients with anxiety (and especially panic) are particularly prone to side-effects with SSRIs/SNRIs</li> <li>Advise the patient that anxiety may get worse before it gets better</li> <li><b>Almost always start low, e.g. 5mg of Fluoxetine, with slow further increases</b></li> <li>May need to use a benzodiazepine while initiating and titrating the antidepressant</li> <li>Advise the patient that <b>treatment of up to 12 weeks</b> may be needed to assess efficacy though non-response in 4 weeks in anxiety is informative</li> </ul>

Baldwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear 	
NHS Foundation Trust	
β blockers	
Anxiety Disorders	<ul style="list-style-type: none"> <li>Propranolol <ul style="list-style-type: none"> <li>Useful for anticipatory (performance) anxiety</li> <li>Does <u>not</u> treat the underlying condition of anxiety disorder</li> <li>Do <b>NOT</b> prescribe for panic disorder</li> </ul> </li> </ul>

Niraj Ahuja, 18th March 2015

## Benzodiazepines

- Efficacy in anxiety, panic and social anxiety disorders
- For those not responding to at least 3 previous treatments, with persistent, severe, distressing and impairing anxiety symptoms
- Risks
  - Sedation
  - Amnesia / cognitive impairment
  - Disinhibition / increase in aggression
  - Dependence / Tolerance
  - Under-treatment and worsening of depression
- Recent DVLA guidance (March 2015)

[www.benzo.org.uk](http://www.benzo.org.uk)  
The Ashton Manual

Baldwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015

## Buspirone

- A 5-HT<sub>1A</sub> partial agonist
- Licensed for GAD
  - 15-45mg daily
  - Can not be used PRN
  - Side-effects
  - Especially useful in benzodiazepine naïve
- Do **NOT** prescribe in panic disorder (can make it worse)

Niraj Ahuja, 18th March 2015

## Antipsychotics


- Quetiapine
  - Evidence in GAD but not licensed
- Risperidone
- Olanzapine
- Older drugs (not recommended)
  - Flupentixol
  - Trifluoperazine

Niraj Ahuja, 18th March 2015

## Pregabalin

- Binds to the  $\alpha 2\delta$  subunit of voltage-sensitive calcium channels (VSCCs)
- Licensed for GAD
  - 2<sup>nd</sup> or 3<sup>rd</sup> choice after SSRIs and SNRIs
- Also helps with co-morbid depressive symptoms
- 150-450mg daily (max 600mg daily)
- Higher doses may be associated with higher response rates (Baldwin et al 2014)

Niraj Ahuja, 18th March 2015



Northumberland, Tyne and Wear NHS Foundation Trust

### Panic disorder

**Anxiety Disorders**

- Detection:
  - In panic disorder, look for co-morbid depression and agoraphobia
  - In patients with medically unexplained physical symptoms, look for panic/agoraphobia
- Psychological treatment: CBT
- Drug treatment
  - SSRIs (All)
  - Some TCAs (e.g. Clomipramine, Lofepramine)
  - Venlafaxine, Reboxetine
  - Benzodiazepines (e.g. Diazepam, Lorazepam)
  - Valproate, Gabapentin
  - Do **NOT** prescribe Propranolol, Buspirone, Bupropion

Baldwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust

### Panic Disorder

**Anxiety Disorders**

	Licensed (BNF)	BAP Guidance
Fluoxetine		YES
Citalopram	YES	YES
Escitalopram	YES	YES
Fluvoxamine		YES
Sertraline		YES
Paroxetine	YES	YES
Venlafaxine		YES
Reboxetine		YES
Valproate		YES
Gabapentin		YES
Tricyclic Antidepressants		YES (Clomipramine, Desipramine, Imipramine, Lofepramine)
Benzodiazepines		YES (Diazepam, Lorazepam, Alprazolam, Clonazepam)

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust

### Specific (Simple) Phobia

**Anxiety Disorders**

- Detection: Look for
  - Number of fears and degree of impairment/severity
  - Co-morbid disorders
- Psychological treatment: Exposure, CBT
- Drug treatment
  - SSRIs (e.g. Paroxetine)
  - Benzodiazepines – contradictory evidence (may both increase and decrease the effectiveness of exposure treatment)

Baldwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015



Anxiety Disorders	Northumberland, Tyne and Wear <small>NHS Foundation Trust</small>		
	Specific (Simple) Phobia		
		Licensed (BNF)	BAP Guidance
	Fluoxetine		
	Citalopram		
	Escitalopram		YES
	Sertraline		
	Paroxetine		YES

Niraj Ahuja, 18th March 2015

Anxiety Disorders	Northumberland, Tyne and Wear <small>NHS Foundation Trust</small>		
	Social anxiety disorder		
	<ul style="list-style-type: none"> <li>Detection: <ul style="list-style-type: none"> <li>Assess degree of impairment/severity (vs. shyness)</li> <li>Co-morbid depression</li> <li>Ask for social anxiety in depression, panic restricted to social situations, alcohol/cannabis misuse</li> </ul> </li> <li>Psychological treatment: CBT</li> <li>Drug treatment <ul style="list-style-type: none"> <li>1<sup>st</sup> line – SSRIs</li> <li>Venlafaxine, Phenelzine, Moclobemide, Benzodiazepines, Gabapentin, Pregabalin, and Olanzapine</li> </ul> </li> <li>Routine prescription of higher doses <u>NOT</u> recommended but individual patients may benefit from higher doses</li> <li><u>Avoid</u> prescribing Atenolol or Buspirone</li> </ul>		

Baldwin et al (2014) BAP Guidelines  
Niraj Ahuja, 18th March 2015

Anxiety Disorders	Northumberland, Tyne and Wear <small>NHS Foundation Trust</small>		
	Social Anxiety Disorder		
		Licensed (BNF)	BAP Guidance
	Fluoxetine		YES
	Citalopram		
	Escitalopram	YES	YES
	Fluvoxamine		YES
	Sertraline		YES
	Paroxetine	YES	YES
	Venlafaxine	YES (XL)	YES
	Clomipramine	YES	YES
	Moclobemide	YES	YES
	Phenelzine		YES
	Benzodiazepines		YES (Bromazepam, Clonazepam)
	Olanzapine		YES
	Gabapentin		YES
	Pregabalin		YES

Niraj Ahuja, 18th March 2015

Anxiety Disorders	Northumberland, Tyne and Wear <small>NHS Foundation Trust</small>		
	PTSD		
	<ul style="list-style-type: none"> <li>Detection: <ul style="list-style-type: none"> <li>Ask for trauma in mental health presentations</li> <li>Co-morbid depression</li> </ul> </li> <li>Psychological treatment: <ul style="list-style-type: none"> <li>Trauma focused CBT, EMDR</li> </ul> </li> <li>Drug treatment: <ul style="list-style-type: none"> <li>1<sup>st</sup> line - SSRIs (Paroxetine, Sertraline) <ul style="list-style-type: none"> <li>Do not routinely prescribe high doses of SSRIs</li> </ul> </li> <li>Venlafaxine</li> <li>If no response, augment with Olanzapine, Risperidone or Prazosin</li> </ul> </li> </ul>		

Baldwin et al (2014) BAP Guidelines  
Niraj Ahuja, 18th March 2015

PTSD	Licensed (BNF)	BAP Guidance
Fluoxetine		+/-
Citalopram		-
Escitalopram		-
Sertraline		YES
Paroxetine		YES
Mirtazapine		+/-
Venlafaxine		YES

# Anxiety Disorders

OC

- Detection:
  - Assess time spent in OC behaviour, distress, impairment and attempted resistance
  - Ask for OC symptoms in depression and vice versa
- Psychological treatment: CBT, Exposure
- Drug treatment:
  - 1<sup>st</sup> line: SSRIs
  - Clomipramine may be slightly more efficacious than SSRIs but has more side effects (also supply problems)
  - Increase SSRI dose if insufficient response at lower dosage; may need higher dose
  - SSRI augmentation with an antipsychotic (e.g. Risperidone) or other drugs
  - Combine SSRI/Clomipramine with CBT to maximise efficacy


Northumberland, Tyne and Wear  
NHS Foundation Trust



NHS

Badalwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust		
OCDD		
	Licensed (BNF)	BAP Guidance
Fluoxetine	YES	YES
Citalopram		YES
Escitalopram	YES	YES
Sertraline	YES	YES
Paroxetine	YES	YES
Fluvoxamine	YES	YES
Venlafaxine		+/-
Clomipramine	YES	YES





Northumberland, Tyne and Wear NHS Foundation Trust

## Risk of Suicide

- Actively ask for ideas/plan/intent of suicide
- Ensure knowledge of how to seek help promptly e.g. Samaritans, Crisis Resolution and Home Treatment (CRHT) Team
- If no suicidal risk, review in 2 weeks
- If suicidal risk or age <30, weekly review till risk no longer clinically important

Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust

## Anxiety Disorders


GAD	At least 18 Months
Panic disorder	At least 6 Months
Agoraphobia	
Specific phobia	
Social anxiety	At least 6 Months
OCD	At least 12 Months
PTSD	At least 12 Months
Adjustment disorder	

Duration of Treatment in those who have responded to treatment is uncertain

- When stopping treatment, taper the dose gradually over an extended period (usually up to 3 months) to avoid discontinuation symptoms

Baldwin et al (2014) BAP Guidelines

Niraj Ahuja, 18th March 2015



- Northumberland, Tyne and Wear NHS Foundation Trust
- ## Drugs causing SS
- ↑ Serotonin
    - L-Tryptophan, Amphetamines (e.g. Ecstasy), Cocaine, L-Dopa, Meperidine (Pethidine), Sibutramine, Buspirone, Triptans, Ergot Alkaloids, Fentanyl, LSD
  - ↑ Postsynaptic Receptor Sensitivity
    - Lithium, Valproate
  - ↓ Metabolism
    - MAOIs, Linezolid (Antibiotic), Ritonavir
  - ↓ Reuptake
    - Cocaine, Ecstasy, Meperidine (Pethidine), Tramadol, Pentazocine, SSRIs, SNRIs, TCAs, Trazodone, Bromocriptine, St John's Wort, Ondansetron, Granisetron, Panax Ginseng, Dextromethorphan
- Niraj Ahuja, 18th March 2015

- Northumberland, Tyne and Wear NHS Foundation Trust
- ## Anxiety Disorders
- ### When to Refer to....
- Secondary care MH services
    - Insufficient experience to manage the condition
    - $\geq 2$  treatments have not resulted in improvement
    - Severe co-existing depression, risk of suicide or self neglect
    - Medical co-morbidity or drug interaction issues
    - Interventions not available in primary care
  - Tertiary care specialist MH services
    - Complex, severe, enduring and treatment-resistant anxiety disorders not responding to treatment options in secondary care
- Niraj Ahuja, 18th March 2015

Northumberland, Tyne and Wear NHS Foundation Trust

Thank You

Niraj Ahuja, 18th March 2015